Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.46 |
| ▸ | CDK9 | P50750 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | CASP3 | P42574 | 2/20 | 0.46 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.46 |
| ▸ | RELA | Q04206 | 1/20 | 0.46 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.46 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.46 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.46 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.44 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.44 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 6/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3913704 | 1.00 | LMNA (0.46) | LMNASMN1; SMN2CDK9KDM4ENPC1 | |
| SCHEMBL3913706 | 1.00 | LMNA (0.46) | LMNASMN1; SMN2CDK9KDM4ENPC1 | |
| SCHEMBL8222219 | 0.86 | P2RX1 (0.47) | LMNASMN1; SMN2CDK9KDM4ENPC1 | |
| SCHEMBL4510950 | 0.86 | PRKD3 (0.42) | LMNASMN1; SMN2CDK9KDM4ENPC1 | |
| SCHEMBL4510945 | 0.86 | PRKD3 (0.42) | LMNASMN1; SMN2CDK9KDM4ENPC1 | |
| SCHEMBL4498405 | 0.85 | KMT2A (0.49) | LMNASMN1; SMN2CDK9KDM4ENPC1 | |
| SCHEMBL4498417 | 0.85 | KMT2A (0.49) | LMNASMN1; SMN2CDK9KDM4ENPC1 | |
| SCHEMBL4509540 | 0.85 | CDK9 (0.52) | LMNASMN1; SMN2CDK9KDM4ENPC1 | |
| SCHEMBL4509551 | 0.85 | CDK9 (0.52) | LMNASMN1; SMN2CDK9KDM4ENPC1 | |
| SCHEMBL4509563 | 0.85 | CDK9 (0.52) | LMNASMN1; SMN2CDK9KDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247519-A1 | AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-10-01 | — | — | US | disclosed |
| US-20090247519-A1 | AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-10-01 | — | — | US | disclosed |
| US-20090247519-A1 | AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-10-01 | — | — | US | disclosed |
| CN-101479246-A | Amino-ethyl-amino-aryl (AEAA) compounds and their use | CANCER REC TECH LTD (GB) | 2009-07-08 | — | — | CN | disclosed |
| EP-2024333-A2 | AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE | Cancer Research Technology Limited (GB) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007125331-A2 | AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007125331-A2 | AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247519-A1 | AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE | PKD2, PKD1, AADAT | LMNA 2132/4885SMN1; SMN2 4800/4885CDK9 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.